The RNA-binding E3 ubiquitin ligase MEX-3C links ubiquitination with MHC-I mRNA degradation
2012; Springer Nature; Volume: 31; Issue: 17 Linguagem: Inglês
10.1038/emboj.2012.218
ISSN1460-2075
AutoresFlorencia Cano, Helen Bye, Lidia M. Duncan, Karine Buchet-Poyau, Marc Billaud, Mark R. Wills, Paul J. Lehner,
Tópico(s)CAR-T cell therapy research
ResumoArticle3 August 2012Open Access The RNA-binding E3 ubiquitin ligase MEX-3C links ubiquitination with MHC-I mRNA degradation Florencia Cano Florencia Cano Department of Medicine, Cambridge Institute for Medical Research, University of Cambridge, Cambridge, UK Search for more papers by this author Helen Bye Helen Bye Department of Medicine, Cambridge Institute for Medical Research, University of Cambridge, Cambridge, UK Search for more papers by this author Lidia M Duncan Lidia M Duncan Department of Medicine, Cambridge Institute for Medical Research, University of Cambridge, Cambridge, UK Search for more papers by this author Karine Buchet-Poyau Karine Buchet-Poyau Institut Albert Bonniot, CRI INSERM/UJF U823, Rond-point de la Chantourne, La Tronche Cedex, France Search for more papers by this author Marc Billaud Marc Billaud Institut Albert Bonniot, CRI INSERM/UJF U823, Rond-point de la Chantourne, La Tronche Cedex, France Search for more papers by this author Mark R Wills Mark R Wills Department of Medicine, University of Cambridge, Cambridge, UK Search for more papers by this author Paul J Lehner Corresponding Author Paul J Lehner Department of Medicine, Cambridge Institute for Medical Research, University of Cambridge, Cambridge, UK Search for more papers by this author Florencia Cano Florencia Cano Department of Medicine, Cambridge Institute for Medical Research, University of Cambridge, Cambridge, UK Search for more papers by this author Helen Bye Helen Bye Department of Medicine, Cambridge Institute for Medical Research, University of Cambridge, Cambridge, UK Search for more papers by this author Lidia M Duncan Lidia M Duncan Department of Medicine, Cambridge Institute for Medical Research, University of Cambridge, Cambridge, UK Search for more papers by this author Karine Buchet-Poyau Karine Buchet-Poyau Institut Albert Bonniot, CRI INSERM/UJF U823, Rond-point de la Chantourne, La Tronche Cedex, France Search for more papers by this author Marc Billaud Marc Billaud Institut Albert Bonniot, CRI INSERM/UJF U823, Rond-point de la Chantourne, La Tronche Cedex, France Search for more papers by this author Mark R Wills Mark R Wills Department of Medicine, University of Cambridge, Cambridge, UK Search for more papers by this author Paul J Lehner Corresponding Author Paul J Lehner Department of Medicine, Cambridge Institute for Medical Research, University of Cambridge, Cambridge, UK Search for more papers by this author Author Information Florencia Cano1, Helen Bye1, Lidia M Duncan1, Karine Buchet-Poyau2, Marc Billaud2, Mark R Wills3 and Paul J Lehner 1 1Department of Medicine, Cambridge Institute for Medical Research, University of Cambridge, Cambridge, UK 2Institut Albert Bonniot, CRI INSERM/UJF U823, Rond-point de la Chantourne, La Tronche Cedex, France 3Department of Medicine, University of Cambridge, Cambridge, UK *Corresponding author. Cambridge Institute for Medical Research, University of Cambridge, Addenbrooke's Hospital, Hills Road, Cambridge CB2 0XY, UK. Tel.:+44 1223 762113; Fax:+44 1223 762640; E-mail: [email protected] The EMBO Journal (2012)31:3596-3606https://doi.org/10.1038/emboj.2012.218 PDFDownload PDF of article text and main figures. Peer ReviewDownload a summary of the editorial decision process including editorial decision letters, reviewer comments and author responses to feedback. ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinked InMendeleyWechatReddit Figures & Info RNA-binding E3 ubiquitin ligases were recently identified, though their function remains unclear. While studying the regulation of the MHC class I (MHC-I) pathway, we here characterize a novel role for ubiquitin in mRNA degradation. MHC-I molecules provide ligands for both cytotoxic T-lymphocytes as well as natural killer (NK) cells, and play a central role in innate and adaptive immunity. MHC-I cell-surface expression is closely monitored by NK cells, whose killer immunoglobulin-like receptors encode MHC-I-specific activatory and inhibitory receptors, implying that MHC-I expression needs to be tightly regulated. In a functional siRNA ubiquitome screen we identified MEX-3C, a novel RNA-binding ubiquitin E3 ligase, as responsible for the post-transcriptional, allotype-specific regulation of MHC-I. MEX-3C binds the 3′UTR of HLA-A2 mRNA, inducing its RING-dependent degradation. The RING domain of MEX-3C is not required for HLA-A2 cell-surface downregulation, but regulates the degradation of HLA-A2 mRNA. We have therefore uncovered a novel post-transcriptional pathway for regulation of HLA-A allotypes and provide a link between ubiquitination and mRNA degradation. Introduction Cell-surface MHC-I provides key ligands for the different receptor families on CTL and NK cells. Signals received by the killer cell immunoglobulin-like receptors (KIRs) balance the NK-cell response between tolerance of healthy cells and killing of unhealthy cells (Parham, 2005). Since small changes in MHC-I levels affect susceptibility to NK killing (Holmes et al, 2011), surface expression of MHC-I must be finely regulated at each stage of the antigen-presentation pathway (Wearsch and Cresswell, 2008), and precise regulation of MHC-I expression is essential for cell survival. Post-translational modification of MHC-I molecules by ubiquitin provides a potent mechanism for regulating MHC-I turnover and several viral as well as cellular ubiquitin E3 ligases (Randow and Lehner, 2009) regulate MHC-I assembly in the endoplasmic reticulum and at the cell surface. Although ubiquitin is best recognized for its role in post-translational protein regulation, a potential role in the regulation of RNA stability has emerged from the finding that at least 15 E3 ubiquitin ligases encode predicted RNA-binding domains (RBDs) (Cano et al, 2010). While there is some understanding of how these proteins regulate mRNA, their requirement for E3 ligase activity is unclear. Turnover of AU-rich cytokine mRNAs is dependent on ubiquitination (Laroia et al, 2002), though the link between mRNA turnover and ubiquitination is not defined. Roquin, an RNA-binding E3 ligase regulates Icos mRNA stability through the repressive action of a particular miRNA (miR-101) (Vinuesa et al, 2005; Yu et al, 2007), though again, the requirement for its E3 ligase activity remains unclear. MHC-I ubiquitination is involved in the post-translational regulation of MHC-I assembly, but ubiquitin is not known to play a role in the transcriptional or post-transcriptional regulation of MHC-I. Our recent experiments showed that ubiquitin is involved in the regulation of cell-surface MHC-I, since overexpression of a ubiquitin mutant markedly increased cell-surface HLA-A2 (Duncan et al, 2010). We now extend these findings, and in a functional siRNA screen identify MEX-3C, a novel RNA-binding E3 ubiquitin ligase, as responsible for the post-transcriptional regulation of common HLA-A allotypes. MEX-3C is highly expressed in cells of the innate immune system, in particular activated NK cells, and affects the threshold of killing by these cells. We show that MEX-3C binds and induces the RING-dependent degradation of HLA-A2 mRNA through its 3′UTR. The RING domain of MEX-3C is not required for HLA-A2 surface downregulation, but is required for HLA-A2 mRNA degradation. These results reveal a novel mechanism for MHC-I allotype-specific regulation and provide, for the first time, a link between ubiquitination and mRNA decay. Results The Ubiquitin-I44A mutant identifies a role for post-transcriptional regulation of HLA-A2 in HEK293 cells We recently showed that the I44A ubiquitin mutant (UB-I44A), which has a mutation in its hydrophobic binding surface, causes a dramatic increase in cell-surface HLA-A2 (Figure 1A and Duncan et al, 2010) in HEK293 cells, with no effect on HLA-B/C or -E (Duncan et al, 2010). Whether ubiquitin is required for the transcriptional or post-transcriptional regulation of MHC-I is unknown. To investigate this further, we used quantitative RT–PCR to show that UB-I44A transfection markedly increased HLA-A2 mRNA levels in these cells (Figure 1B). To our surprise, this increase in mRNA did not reflect de-novo initiation of HLA-A2 transcription, as neither wild-type ubiquitin nor the UB-I44A mutant increased reporter luciferase activity in cells expressing luciferase driven by the HLA-A*0201 promoter (pGL3-A230; Gobin and van den Elsen, 2001) (Figure 1C). Transfection of the positive control MHC class II transactivator (CIITA) significantly increased luciferase activity (Figure 1C). The increase in HLA-A2-specific mRNA was therefore most likely to be post-transcriptional, rather than due to increased HLA-A2 mRNA transcription. Since these findings suggested a role for ubiquitin in the regulation of HLA-A2 mRNA stability, we screened HEK293 cells with a custom siRNA library, targeting the putative E3 ubiquitin ligase family (Stagg et al, 2009) to identify the ubiquitin E3 ligase responsible. Figure 1.The Ubiquitin-I44A mutant induces a post-transcriptional increase in HLA-A2 mRNA. (A) Cytofluorometric analysis of cell-surface HLA-A2 expression in HEK293 cells expressing GFP-tagged UB-I44A or wt-UB. Cells were labelled with mAb BB7.2 for HLA-A2 expression. Red boxes show % of Ubiquitin–GFP expressing cells. (B) UB-I44A expression increases HLA-A2 mRNA levels. HEK293 cells were sorted by GFP levels, a surrogate marker for ubiquitin expression. HLA-A2 transcripts were measured by qRT–PCR and normalized against GAPDH levels, using the ddCt method. Relative transcript levels are visualized in a 1.8% agarose gel (top panel) and expressed as mean±s.d. (bottom panel). Data are representative of three experiments. NT: no template control. (C) UB-I44A does not affect HLA-A2 promoter activity. HEK293 cells were co-transfected with pGL3-A230, a luciferase reporter driven by the HLA-A*0201 promoter, together with CIITA (positive control), empty vector (mock control) or the wild-type (wt) and UB-I44A ubiquitin constructs. Luciferase activity was determined 48 h post-transfection. Results are relative to mock control levels (set as 1) and expressed as mean±s.d. of three independent experiments (N=3). Download figure Download PowerPoint A targeted siRNA screen identifies MEX-3C, a novel RNA-binding E3 ubiquitin ligase, as involved in HLA-A2 regulation The rationale of the screen was our prediction that depletion of the E3 ligase required for HLA-A2 regulation would increase cell-surface HLA-A2 levels, similar to the effect observed with the UB-I44A mutant (Figure 1A). We screened a ubiquitome library, specific for RING and Hect E3 ligases. Of the 375 E3 ligases screened, depletion of only one, MEX-3C, significantly increased HLA-A2 surface levels (Figure 2A and B), with a Z-score (5.23) significantly above the Bonferroni-corrected P-value threshold (P=0.05) of 3.82. The increased cell-surface HLA-A2 expression was achieved with four independent MEX-3C siRNAs (Supplementary Figure S1A). Effective on-target depletion of endogenous MEX-3C mRNA was detected by qRT–PCR; with no effect on its homologues MEX-3A, MEX-3B and MEX-3D (Supplementary Figure S1B). Although the MEX-3C-specific antibody was insufficiently sensitive to detect endogenous MEX-3C in HEK293s, effective depletion of exogenous myc–MEX-3C was seen by immunoblot, confirming specificity of the siRNA (Figure 2C), which had no activity against the related myc–MEX-3D (data not shown). Figure 2.A targeted siRNA screen identifies a role for MEX-3C, a novel RNA-binding E3 ubiquitin ligase, in HLA-A2 regulation. (A) siRNA-mediated depletion of MEX-3C significantly increases cell-surface HLA-A2 expression. The left bar chart shows the Z-scores for the 375 E3 ligases screened in three independent experiments. Of the 375 E3 ligases screened, only MEX-3C depletion gave a significant increase in HLA-A2 expression. The graph on the right shows the top five Z-scores. MEX-3C's Z-score (5.23) was significantly above the Bonferroni-corrected P-value threshold (P=0.05) of 3.82 (dashed line). (B) Flow cytometric analysis of cell-surface HLA-A2 levels in mock (dashed line) versus siRNA-treated cells (solid line). Isotype control (solid grey). (C) Stable shRNA-mediated depletion of MEX-3C increases cell-surface HLA-A2. (Left) Cytofluorometric analysis of HLA-A2 surface levels in parental (mock shRNA depleted, dashed line) HEK293 and cells stably transduced with a shRNAmir against MEX-3C (shMEX-3C; solid line). (Right) Immunoblot analysis of MEX-3C in HEK293 cells expressing myc-tagged MEX-3C or control cells (mock), both stably transduced with shMEX-3C. The shMEX-3C sequence is identical to the targeting oligonucleotide #2 of the original screening pool. β-Actin was used as loading reference levels. Download figure Download PowerPoint The MEX-3 protein family of evolutionarily conserved RNA-binding E3 ligases are recruited to P-bodies and involved in post-transcriptional regulation (Buchet-Poyau et al, 2007). There are four human MEX-3 proteins, each containing two tandem repeat mRNA-binding KH domains and a C-terminal E3 ubiquitin ligase RING domain (Figure 3A; Buchet-Poyau et al, 2007). MEX-3C directly binds RNA via the KH domains (Buchet-Poyau et al, 2007), though the sequence specificity and affinity is undefined. MEX-3C also interacts directly with the argonaute AGO1 and AGO2 proteins, co-immunoprecipitates poly(A)-binding protein (PABP) and shuttles from the nucleus to the cytoplasm via the CRM-1 complex (Buchet-Poyau et al, 2007). Figure 3.MEX-3C's ubiquitin ligase activity is required for HLA-A2 mRNA degradation. (A) Schematic representation of MEX-3C protein. Asterisks indicate the residues mutated in the mutKH MEX-3C (G249D; G343D), while the arrowhead indicates the position of the premature stop codon in RINGless MEX-3C (1–636). (B) Over-expression of wild-type and RINGless MEX-3C reduce HLA-A2 levels in HEK293T cells. Cytofluorometric analysis of cell-surface HLA-A2 in HEK293T cells expressing the indicated MEX-3C cDNAs, co-transfected with GFP cDNA (10%) as a surrogate marker for MEX-3C expression (see also Supplementary Figure S1C for MEX-3C immunoblots). TfR levels were measured as control. HLA-A2 geometric fluorescent means (GFM) in transfected GFPhigh cells for the empty vector control and wtMEX-3C were 90.5 and 29.4, respectively, resulting in a three-fold cell-surface downregulation of HLA-A2. A similar effect was seen in cells transfected with RINGless MEX-3C (GFM=43.2); while treatment with MEX-3C KH mutant caused only a minor decrease in cell-surface HLA-A2 expression (GFM=74.8). (C) The RING domain of MEX-3C is required for HLA-A2 mRNA degradation. Endogenous HLA-A2 mRNA levels were analysed by qRT–PCR from sorted GFPhigh (MEX-3C (includes wild-type or RINGless MEX-3C) expressing) and GFP− (control) populations 48 h post-transfection (see also Supplementary Figure S1D for MEX-3C protein levels). A significant reduction in HLA-A2 transcript levels (0.44±0.10; N=5; P-value=0.0001) was seen in wtMEX-3C expressing cells when compared with control cells (set at 1±0.25) all normalized to GAPDH. In contrast, RINGless MEX-3C shows a modest increase in HLA-A2 transcripts (1.23±0.14; N=5) compared with control cells. Results are expressed as the mean±s.d. of five independent experiments (***P-value=0.0001). Download figure Download PowerPoint Overexpression of MEX-3C reduces HLA-A2 levels in HEK293T cells Since depletion of endogenous MEX-3C increased HLA-A2 expression, we examined how MEX-3C overexpression affects HLA-A2 in HEK293T cells, which have higher resting HLA-A2 levels than HEK293s. As predicted from the MEX-3C RNAi experiments, exogenous expression of wtMEX-3C (together with pMax–GFP at a 10:1 ratio so that GFP expression provides a surrogate marker for exogenous MEX-3C) decreased both HLA-A2 mRNA and surface HLA-A2 expression (three-fold) (Figure 3B and C). A similar decrease in surface HLA-A2 expression was seen in cells transfected with RINGless MEX-3C (aa 1–636), which has no ubiquitination activity. In contrast, the MEX-3C KH mutant (G249D; G343D), with single-point mutations in each of the two RBDs, caused only a minor decrease in cell-surface HLA-A2 (Figure 3B; Supplementary Figure S1C). The RING domain of MEX-3C is required for HLA-A2 mRNA degradation MEX-3C's E3 ubiquitin ligase activity was readily confirmed by immunoblotting (Supplementary Figure S2A). However, since wt and RINGless MEX-3C both decreased cell-surface HLA-A2 expression, the role of MEX-3C's C-terminal RING domain is unclear (Figure 3B), raising the question whether the E3 ligase activity is required for HLA-A2 mRNA regulation? MEX-3C originates from an evolutionarily conserved family of RNA-binding proteins. The founder member, MEX-3 from Caenorhabditis elegans is a key effector of cell polarity, controlling the spatial patterning of PAL-1 in the nematode embryo. Disruption of the mex-3 locus is embryonic lethal and MEX-3 is thought to prevent translation of the PAL-1 mRNA through binding the PAL-1 3′UTR (Draper et al, 1996; Hunter and Kenyon, 1996). The two KH domains required for RNA binding retain ∼80% sequence identity with their four human MEX-3 (hMEX-3A–D) paralogues. Evolutionary diversification from C. elegans lead to the acquisition of a C-terminal RING finger, evident in the Drosophila orthologue, with subsequent expansion from a single dMex-3 (RNA-binding+RING finger domain) to four genes on different chromosomes in higher eukaryotes, including humans. To try and identify a role for the MEX-3C RING, we measured endogenous HLA-A2 mRNA in cells expressing high levels of MEX-3C (sorted for GFPhigh) and GFP− (control) populations following MEX-3C transfections (Figure 3C). A significant reduction in HLA-A2 mRNA is seen in wtMEX-3C cells compared with control cells (Figure 3C). In contrast, cells expressing RINGless MEX-3C showed no decrease in HLA-A2 mRNA, despite, like wtMEX-3C showing reduced cell-surface HLA-A2 levels (Figure 3B; Supplementary Figure S1D). Indeed, these cells show a modest increase in HLA-A2 mRNA, confirming an absolute requirement of MEX-3C's RING in mRNA degradation. Therefore, degradation of HLA-A2 mRNA by MEX-3C is dependent on a functional RING domain and implies a critical role for ubiquitin ligase activity in mRNA decay. MEX-3C binds HLA-A2 mRNA in vivo To confirm that the decreased HLA-A2 mRNA levels seen with wtMEX-3C was due to mRNA decay, and not decreased transcription, we used the previously described reporter assay (Figure 1C) to show that neither wt nor RINGless MEX-3C affected HLA-A*0201 promoter activity (Figure 4A). MEX-3C binds mRNA through its KH domains (Buchet-Poyau et al, 2007), and we confirmed a direct interaction between both wt and RINGless MEX-3C and HLA-A2 mRNA by RT–PCR (Buchet-Poyau et al, 2007), whereas no HLA-A2-specific mRNA was immunoprecipitated with the MEX-3C KH mutant (Figure 4B). Furthermore, the closely related HLA-B mRNA was not detected in MEX-3C immunoprecipitates (Figure 4B). Figure 4.MEX-3C regulates HLA-A2 levels through its mRNA 3′UTR. (A) MEX-3C does not affect HLA-A2 promoter activity. HEK293Ts were co-transfected with a luciferase reporter driven by the HLA-A*0201 promoter, together with controls or the indicated MEX-3C constructs. (B) MEX-3C binds HLA-A2 mRNA in vivo. MEX-3C was immunoprecipitated (IP) from HEK293Ts expressing the indicated myc-tagged–MEX-3C cDNAs. RT–PCR was performed on either total RNA from lysates, or following IP with anti-myc antibody (top panel). MEX-3C immunoblots were performed on lysates or anti-myc IPs (bottom panel). NT: No template. (C) MEX-3C regulates HLA-A2 levels by its mRNA 3′UTR. The HLA-A*0201-3′UTR was cloned downstream of firefly luciferase and co-transfected into HEK293Ts with the indicated MEX-3C constructs. Luciferase activity in wtMEX-3C expressing cells (0.06±0.001; N=4; P-value =0.0005) showed a 16-fold decrease compared with control cells (set as 1). RINGless-MEX-3C (0.10±0.002; N=4; P-value=0.006) was also markedly decreased, an effect that was partially abrogated by the mutKH-MEX-3C (0.69±0.01; N=4). **P-value=0.0005 versus Control; *P-value=0.001 versus wtMEX-3C. Results are expressed as the mean±s.d. of four independent experiments. (D) The RING domain of MEX-3C is required for mRNA degradation. FF-Luc-HLA-A2-3′UTR mRNA levels were analysed by qRT–PCR from cells expressing the different MEX-3C mutants as indicated. Results are expressed as the mean±s.d. of three independent experiments. **P-value <0.001. (E) MEX-3C associates with the DUB USP7. HEK293Ts were co-transfected with Strep-His-wt or RINGless MEX-3C. Cells were lysed in 1% NP-40 and immunoprecipitated on Streptactin beads (MEX-3C IPs) or for endogenous USP7, and immunoblotted for USP7 and MEX-3C. (F) Cytofluorometric analysis of cell-surface HLA-A2 in HEK293Ts expressing wtMEX-3C and/or USP7 cDNAs. GFP expression is a surrogate marker for MEX-3C and USP7 expression. TfR levels were measured as control. The HLA-A2 geometric fluorescent means in transfected (GFP+) cells are: Mock=177; MEX-3C only=48; USP7 only=164 and MEX-3C+USP7=45.7. (G) The Ubiquitin ligase activity of MEX-3C is required for HLA-A2 mRNA degradation. Endogenous HLA-A2 mRNA levels were analysed by qRT–PCR from unsorted cells expressing MEX-3C and/or exogenous USP7. A significant accumulation of HLA-A2 transcripts (3.1±0.2; compared with control) was detected when MEX-3C and USP7 were co-expressed. This effect was abrogated by inhibiting USP7 activity. Results are expressed as the mean±s.d. of three independent experiments. *P-value<0.05 versus control; #P-value<0.05 versus USP7+MEX-3C cells. (H) USP7 inhibition results in a rapid decrease in HLA-A2 mRNA levels (0.36±0.1; versus control=1). NKL cells (see later) were incubated with USP7 inhibitor P045204 (10 μM for 4 h). Endogenous HLA-A2 mRNA levels were analysed by qRT–PCR. Results are expressed as the mean±s.d. of three independent experiments. **P-value<0.001. Download figure Download PowerPoint MEX-3C regulates HLA-A2 levels through its mRNA 3′UTR Since MEX-3C binds poly-A-binding protein, potentially directing it to the 3′UTR of mRNAs (Buchet-Poyau et al, 2007), we wanted to determine whether MEX-3C could regulate firefly luciferase protein expression (measured as luciferase activity) through the HLA-A2 3′UTR. The HLA-A*0201 3′UTR was cloned downstream of the 3′region of the firefly (FF) luciferase gene in the pGL3 control vector, which utilizes FF luciferase as the primary reporter to monitor mRNA regulation. Renilla luciferase was used to normalize transfection levels. Both wt and RINGless MEX-3C markedly downregulate FF luciferase activity (Figure 4C), an effect almost completely abrogated by the mutKH MEX-3C (0.69±0.01), in accordance with its decreased mRNA binding. These results are consistent with our previous data (Figure 3B) showing that wt and RINGless MEX-3C reduce cell-surface HLA-A2 through the HLA-A2 3′UTR. While expression of both wt and RINGless MEX-3C had decreased surface HLA-A2 protein expression (Figure 3C), only wtMEX-3C had decreased HLA-A2 transcripts. This important finding was further examined by measuring luciferase mRNA levels in the FF-Luc-HLA-A2 3′UTR constructs, following expression of wt and RINGless MEX-3C, which both decrease FF-luciferase protein levels (Figure 4C). As seen with endogenous HLA-A2 transcripts (Figure 3C), wt MEX-3C expression markedly decreased FF-Luc-HLA-A2 3′UTR mRNA (Figure 4D). In contrast, following RINGless MEX-3C expression, there was no decrease in FF-Luc-HLA-A2 3′UTR mRNA, but a marked elevation in FF-Luc-HLA-A2 3′UTR mRNA levels is evident (Figure 4D), despite almost undetectable FF-luciferase protein levels (Figure 4C). Indeed, expression of RINGless MEX-3C caused an eight-fold increase in FF-Luc-HLA-A2 3′UTR mRNA compared with control (Figure 4D), confirming the requirement of MEX-3C's RING, and by implication E3 ligase activity, in mRNA degradation. Taken together (Figures 3C and 4D), our results emphasize that ubiquitin ligase activity is required for mRNA degradation. In the absence of the RING, RNA binding by MEX-3C is sufficient to prevent translation or ‘sequester’ the bound mRNA. Under these circumstances, the mRNA is neither translated nor degraded, causing a decrease in HLA-A2 protein expression. This situation appears analogous to MEX-3's activity in C. elegans, prior to MEX-3's evolutionary acquisition of a RING, where translation of its substrate PAL-1 mRNA is repressed but PAL-1 mRNA is not degraded, as seen with RINGless MEX-3C on HLA-A2 mRNA. We infer that the MEX-3 gene products were initially RNA-binding and later acquired ubiquitin E3 ligase activity, which not only prevents mRNA translation, but now also promotes degradation. USP7 is the DUB for MEX-3C, and confirms the requirement of E3 ubiquitin ligase activity in HLA-A2 mRNA decay To identify additional MEX-3C-binding partners, we performed a MEX-3C (Streptactin) pull-down followed by mass spectrometry analysis (Supplementary Table S1). We found that both wt and RINGless MEX-3C bind the deubiquitinating (DUB) enzyme USP7, a finding readily confirmed by immunoprecipitation (Strep-MEX-3C or endogenous USP7) and immunoblotting in both directions (Figure 4E). The interaction was further confirmed in NK cells where endogenous MEX-3C associates with endogenous USP7 (see later and Supplementary Figure S7A). Neither overexpression nor depletion of USP7 affected MEX-3C protein levels (Supplementary Figure S7B and C). To determine how this DUB might regulate MEX-3C's activity, we overexpressed USP7 together with wtMEX-3C. A phenotype similar to that observed with RINGless MEX-3C is seen, in that HLA-A2 cell-surface expression was decreased (Figure 4F), but no HLA-A2 mRNA degradation was seen (Figure 4G). Indeed, expression of USP7, when co-expressed with wtMEX-3C, caused a significant three-fold increase in endogenous HLA-A2 mRNA compared with the control in unsorted HEK293T cells (Figure 4G). Conversely, HLA-A2 mRNA levels decreased when USP7 activity was inhibited in HEK293T cells and NKL cells (see later and Figure 4G and H). In the presence of the USP7 DUB, more HLA-A2 is bound to wtMEX-3C, as overexpression of USP7 increases the amount of HLA-A2 mRNA co-immunopreciptated with MEX-3C (as measured by qRT–PCR) (Supplementary Figure S7D). Ubiquitin ligase activity is therefore required for mRNA degradation and can be prevented either by removal of the RING (RINGless MEX-3C) or by overexpression of the USP7 DUB. These results also imply that USP7 has DUB activity against either MEX-3C itself, or other substrate(s) of MEX-3C. MEX-3C is induced in activated human NK cells Mex-3C mRNA is reported to be preferentially expressed in cells of the immune system, particularly NK cells (http://biogps.gnf.org). Immunoblot analysis of MEX-3C in primary human NK cells and two NK cell lines (NK-92; NKL) was consistent with this transcriptional analysis (Figure 5). Despite not being detected in freshly isolated primary NK cells, MEX-3C was markedly upregulated following NK cell activation, with MEX-3C identity confirmed by siRNA-mediated depletion (Figure 5A). This IL-2 responsive expression of MEX-3C was also seen in NK-92 and NKL cells, peaking 24 h post-stimulation, and downregulated by 48 h (Figure 5B). These results are specific to the NK lineage, as MEX-3C expression was not detected in IL-2-activated primary CD4+ T-cells (Supplementary Figure S3). Figure 5.MEX-3C specifically regulates HLA-A but not HLA-B or HLA-C expression in primary human NK cells and modulates NK cell killing. (A) Immunoblot analysis of MEX-3C from freshly isolated and activated primary human NK cells. NK cells were purified from healthy blood donors and activated for 1–3 weeks. MEX-3C siRNA nucleofection results in efficient depletion in NK cells at 72 h post-nucleofection. (B) Immunoblot analysis of MEX-3C in the NK-92 (upper panel) and NKL cell lines (lower panel), following stimulation with IL-2 (350 U/ml) at the different time points shown. (C) Immunoblot analysis of MEX-3C downregulation in NKL cells after 72 h post-nucleofection. (D) Depletion of MEX-3C in NKL cells results in an allotype-specific increase of surface HLA-A2. Cytofluorometric analysis of HLA-A2, -B, -C, and TfR levels in mock (dashed line) and siMEX-3C cells (solid line). Isotype control (solid grey). (E) MEX-3C depletion increases HLA-A2 but not HLA-B mRNA levels in NKL cells. HLA-A2, pan-HLA-B, and MEX-3C mRNA levels were measured by qRT–PCR in mock and siMEX-3C nucleofected cells. Quantitative RT–PCR analysis of MEX-3C siRNA knockdown cells showed a significant 2.03±0.56-fold increase in HLA-A2 mRNA levels over mock cells (P-value=0.010, n=3). Transcript levels are relative to GAPDH and normalized to mock levels, set as 1 and expressed as the mean±s.d. of three independent experiments (P-value=0.01). (F) Depletion of MEX-3C increases HLA-A2 mRNA half-life. Mock (dashed line) or siMEX-3C (solid line) treated NKL cells were incubated with Actinomycin D (5 μg/ml). HLA-A2 and HLA-B mRNA levels were measured by qRT–PCR and normalized against HPRT. Results are the mean±s.d. of three independent experiments. (G) Depletion of MEX-3C in primary human NK cells results in an allotype-specific increase of surface HLA-A (HLA-A2 and -A3) but not HLA-B or -C. Cytofluorometric analysis of HLA-A2, -A3, -B, and -C levels in mock (dashed line) and siMEX-3C nucleofected cells (solid line). Isotype control (solid grey). (H) Reduced target cell killing in MEX-3C depleted primary NK cells. 51Cr release assay (percent specific lysis) using mock siRNA (dashed line) or siMEX-3C (solid line) n
Referência(s)